Physician profile
Eric Nghe
NPI 1417466368
$5,353.27
in general payments reported to CMS, 2019-2025
20 companies · $1,600 in 2025
The $1,600 reported for 2025 was more than what 89% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $406 · 2022: $1,014 · 2023: $893 · 2024: $1,440 · 2025: $1,600.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,921 · Education: $12.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,920.80 |
| Education | $12.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $747.06 | 2023-2025 | Auvelity |
| Janssen Pharmaceuticals, INC | $740.09 | 2022-2024 | Invega Sustenna, Invega Trinza, Spravato |
| Teva Pharmaceuticals USA, INC. | $738.04 | 2023-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Abbvie INC. | $541.67 | 2022-2025 | |
| Otsuka America Pharmaceutical, INC. | $518.92 | 2023-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $463.99 | 2022-2025 | Caplyta |
| Lundbeck LLC | $330.16 | 2024-2025 | Rexulti |
| Biogen, INC. | $217.44 | 2021-2024 | Zurzuvae |
| Vanda Pharmaceuticals INC. | $204.58 | 2025 | Fanapt |
| Biohaven Pharmaceutical Holding Company Ltd. | $124.99 | 2022 | |
| Amag Pharmaceuticals, INC. | $124.98 | 2021 | |
| Abbott Laboratories | $114.10 | 2022-2023 | Proclaim |
| Boehringer Ingelheim Pharmaceuticals, INC. | $99.22 | 2021 | |
| Gen-Probe Sales & Service, INC. | $86.46 | 2021 | |
| Janssen Scientific Affairs, LLC | $85.12 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $79.80 | 2023-2024 | Aristada, Lybalvi |
| Indivior INC. | $55.47 | 2022 | |
| Ironshore Pharmaceuticals INC. | $41.44 | 2023 | Jornay Pm |
| Tempus Ai, INC | $21.13 | 2024 | |
| Noven Therapeutics, LLC | $18.61 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Nghe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.